This article discusses two approaches to costing disease and summarizes an incidence-based costing of schizophrenia using 1975 data. Because the presentation of schizophrenia may have changed in the last 16 years, the effects of three possible changes-a reduction in incidence, a transfer to treatment in the community, and an improvement in prognosis-are all entered into the 1975 model and the changes in costs are noted. The decrease in costs is greatest presuming a reduction in incidence, moderate given an improvement in prognosis, and relatively minor given the economies in direct treatment costs likely to follow a transfer to community treatment. Nevertheless, because community treatment might also be associated with an improvement in prognosis, the social issues for medicine implicit in the transfer from hospital to community treatment are discussed.
We have recently argued (Andrews et al. 1990 ) that, with increasing agreement about both diagnostic criteria and the treatments appropriate for a particular diagnosis, the main area of disagreement in mental health care is how services should be organized and where and by whom patients should be treated. This means that while we can now defend the utility of particular treatments, there is a growing debate with administrators and financial controllers as to the resources needed to deliver these treatments. We can no longer depend on clinical data alone to justify a course of action. It is now crucial for clinicians to develop the ability to cost current services and relate these costs to those likely to be incurred if services are changed. The most desirable method of apportioning the resources available would be an allocation based on the costs and benefits of each available policy option.
Cost comparisons of treatments require that we put some monetary value on morbidity and mortality, a concept repugnant to many who argue that life and suffering cannot be measured in monetary terms. This argument ignores the fact that decisions about funding for health programs are constantly being made on the basis of what was done last year, revised in terms of the prevalence or importance of particular diseases. Such arguments always presuppose an economic model in that common diseases are presumed to cost more than rare diseases of equal severity, and important diseases are those that cost more, either because of the high direct cost of treatment or because of the costly consequences of a chronic aftermath.
Direct costs are those associated with treatment such as hospital costs, outpatient costs, nursing care, drugs or other treatments, services of other health professionals, and rehabilitation costs. Direct costs can include some allowance for the capital costs of the buildings and the costs of the service infrastructure, not just the recurrent costs of the particular treatments. Indirect costs are usually confined to the earnings that are foregone on account of illness and are calculated from the time out of the work force or from the degree to which persons must accept lower paid work because of illness. Although this approach is derived from the human capital approach to Reprint requests should be sent to Dr. G. Andrews valuing life as if humans were little more than productive labor resources, it is important to realize that indirect costs are a proxy for the disabling effects of an illness just as direct costs are a proxy for efforts to reduce symptoms. Indirect costs can be further extended by costing the quality of adjusted life-years experienced by the patient and the time and economic burden that an illness may generate for the patient's family or caregivers.
Prevalence versus Incidence Approach
There are two principal approaches to costing disease. In the prevalence approach, disease costs and productivity losses are assigned to the years in which they occur. This type of costing identifies the major contributors to current expenditure. If cost control is the aim of the exercise, this approach allows for identification of possible targets for economizing. If a change in service delivery is being implemented, the prevalence approach allows a comparison of the balance sheets before and after the change. Fein (1958) and Gunderson and Mosher (1975) provide examples of prevalence-based costing of schizophrenia.
In the incidence approach "the stream of costs associated with an illness should be assigned to the year in which the stream begins" (Hartunian et al. 1981, p. 17) . All future direct and indirect costs are estimated and discounted so that they can be measured in the dollars of the year in which the illness first occurs, because once the illness has occurred, the society at one level or another is committed to meet the stream of costs that will be associated with that illness. This approach is useful because it can provide predictions about the likely long-term impact of programs that reduce incidence, make treatment less costly, or improve outcome. Andrews et al. (1985) present an example of an incidence-based costing of schizophrenia.
An Incidence-Based Costing Model
In this article, we will review the results of the Andrews and colleagues' 1985 study and use those data, which were based on conditions in New South Wales (NSW), Australia, in 1975, to investigate three scenarios: a reduction in incidence, a shift to community treatment, and improved outcome. In our previous study we used the incidence-based method of Hartunian et al. (1981) . Direct costs were estimated by obtaining the number of new cases of schizophrenia from a case register (annual incidence, 22/100,000) and calculating the duration and cost of episodes of hospitalization and outpatient care for each patient's lifetime. The average length of stay per admission was estimated to be 135 days, a reliable estimate for 1975, and each patient was expected to average 4.52 admissions in his or her lifetime. The likely outcomes were defined as follows: 25 percent of patients were expected to have a good outcome (60 days in a hospital, 6 months out of the work force, and no further disability); 40 percent of patients were expected to experience a median outcome (600 days in a hospital over their lifetime and an average of only 4 months per year in the work force); and 35 percent of patients were expected to have a poor outcome (1,200 days in a hospital over their lifetime and never able to reenter the work force). The precise details of the method, results, and effects of varying these estimates have been published (Andrews et al. 1985; Hall et al. 1985) . The main results are displayed in table 1 by age and do not, for the purposes of the present exercise, include the costs of the prodrome. The unit of cost is 1 million 1975 U.S. dollars and this unit is maintained throughout all tables to allow direct comparison between models.
The results show that the indirect costs of lost productivity are considerably greater than the direct costs of psychiatric treatment, and that it is the young onset and poor outcome cases that generate the greatest costs in either category. The total cost, $131.5 million, was half the cost of myocardial infarction when that disorder was costed in the same manner, even though schizophrenia is 12 times less common than myocardial infarction. We will now explore the effects of changes in incidence, treatment location, and prognosis on those estimates. Der et al. (1990) argued that the incidence of schizophrenia fell in some countries between 1975 and 1990 , and that it is "the early onset and very severe cases" that are no longer appearing. Their data were on treated incidence, and such data would also be consistent with an apparent drop in incidence because of a gradual lessening in the severity of the condition, so that each year about 3 percent fewer patients than expected contacted specialist services. The estimates in table 1 have been modified to show the effect of such a 40 percent drop in incidence, a drop that is especially noticeable in the young and in the severe cases (see  table 2 ). Thus, no cases appear in the 10-19 age group, half the expected number in the 20-29, and a quarter of the expected number in the 30-39 age group. If these changes are due to a lessening in severity, then some early onset cases will probably show up eventually; hence the incidence in the older age groups is not changed. A reduction in incidence of 40 percent obviously changes the direct and indirect costs by 40 percent but there is an additional factor. The reduction is in the young onset and severe cases, the two most expensive categories. Thus, if one now argues that the size of the poor outcome group is reduced from 35 to 30 percent and the good outcome group increased by the same amount, then there are additional savings in both subsequent-year direct costs and in the indirect costs due to lost productivity. In table 2 the saving from this 40 percent reduction in incidence is estimated to be 47 percent of the original expenditure presuming that location and outcome of treatment remained just as they were in 1975. The location of treatment has not remained constant and the assumptions in table 1 are no longer justified. In Australia the number of psychiatric beds fell by 75 percent during the period 1975 to 1990. Similar decreases in the beds occupied by patients with schizophrenia have occurred, or are occurring, in many other countries. To gauge the effect of this shift to community treatment, we have held the incidence and the prognosis constant and amended the data in table 1 on the assumption that 25 percent of patients will still require the same number of hospital days as was required in 1975, and that the remaining 75 percent who were hospitalized in 1975 will now be accommodated in the community instead of in a hospital. We have used Hafner and Heiden's estimates (1989) , stating that community care on average costs 43 percent of hospital care, to adjust the figures for the direct costs of treatment. Because no change in prognosis is anticipated in this model, no change in indirect costs is allowed (see table 3 ). Even though the direct costs of treatment fall by nearly 50 percent, the overall effect of this change to community treatment is a modest 8 percent drop over the original estimates, simply because we have allowed no change in prognosis and hence no alteration to the indirect costs.
The prognosis, however, also appears to be changing. Regardless of whether the incidence of schizophrenia is falling, there is general agreement that the severe cases of yesteryear are not being seen as frequently. This may be due to changes in the disease, but there are also hints that it could be a consequence of changes in methods for treating patients with this disorder. In the World Health Organization's multicenter trials of the treatment of schizophrenia (Sartorius et al. 1986 ), patients in the developing countries who spent little time in a hospital had a significantly better prognosis than patients in developed countries who tended to be managed as inpatients. Comparisons of acute community treatment compared with hospital treatment or studies in which long-stay patients are discharged into the community have consistently shown that living in the community is curative in ways that living in a hospital is not. As the final part of this exercise we have modeled the effect of a change in prognosis similar to that seen in the developing countries. The number of goodoutcome patients is doubled from our 1975 estimates to 50 percent and the number of median-and pooroutcome patients is set at 25 percent in each category, thus presuming that for every 100 patients, 10 who would have had a poor outcome now experience a median outcome, while 25 of the median outcome group now experience a good outcome. These results are displayed in table 4. Direct costs for the first year were reduced by 16 percent and for subsequent years by 32 percent. Indirect costs for the good outcome cases doubled while those for the median cases were reduced by 37 percent and for the poor cases by 29 percent. The net effect was a 27 percent reduction in cost.
Discussion
Three possible scenarios have been entered into an existing incidencebased costing algorithm. A reduction in incidence of schizophrenia of 40 percent, with treatment location and prognosis held constant, yielded a 47 percent reduction in both direct and indirect costs with a marginal decline in costs per case. A substantial reduction in hospital treatment and transfer to community treatment, with incidence and prognosis held constant, yielded a 43 percent reduction in direct treatment costs (which would satisfy the area health budget), no change in indirect costs, and a disappointing drop of only 8 percent in the overall costs, the cost per case falling by a similar amount. An improvement in prognosis whereby the number of good outcomes was doubled but incidence and location of treatment were held constant in 1975 terms reduced direct, indirect, cost per case, and overall costs by 27 percent. The magnitudes of the changes in incidence, location, and prognosis have been taken from current literature. Given these values it is clear that in economic terms likely changes in incidence have a greater influence than improved prognosis and that both are superior to savings on the direct cost of treatment produced by a change to treatment in the community. To summarize, prevention (table 2) is better than cure (table 4) and both are better than a cheaper treatment (table 3) . It is not surprising therefore that research monies are preferentially given to studies of etiology which may offer clues to prevention, are then given to studies which offer improved treatment, and are only reluctantly given to studies of improved service delivery. But most of us have to deal with a very local environment in which the decisions of the insurer or the fiscal administrator determine what can and cannot be done, an environment in which the priorities outlined above are completely inverted. For accountants, reduction in direct treatment cost is good news, reduction of incidence in the future completely irrelevant, and improvement in prognosis desirable but irrelevant to the pressing need to balance this year's budget.
Separately, none of the scenarios outlined above represents schizophrenia circa 1990, but together they probably do. The severity of the disease does appear to be declining and this would be reflected in lower numbers of patients coming for treatment. Treatment in the community has become usual; and, either because of this or because of the lessening severity or both, the prognosis is improving. Since treatment in the community is the only factor that can be changed directly by our efforts, it is important to be clear about what is meant by the term community treatment. Treatment of new cases is now marked by diagnosis, initiation of drug therapy, resolution of complicating stressors, and initiation of behavioral family therapy, all taking place as office-based procedures (Quality Assurance Project 1984; Falloon 1985) . Hospitalization, if indicated, is characteristically brief so that the patient no longer has the chance to develop any sense of having a permanently damaged identity (Hannan 1991) . Neither has the family nor the workplace the chance to extrude the patient from consideration. Patients who have been hospitalized for considerable periods of time can be discharged into the community and gradually rehabilitated (Andrews et al. 1990) , and those who are homeless can often be encouraged to begin regular treatment and begin a settled living pattern, provided there is some hope of eventually passing as normal (Teesson and Hambridge, submitted for publication).
Although the resources needed for community treatment are considerable, it is still a cheaper alternative than prolonged hospitalization. These resources include highly trained clinicians for individual case mangement, complemented by a web of community crisis and rehabilitation services. The requirement for hospital beds is definite but small. A well-developed psychiatric service for a population of 100,000 may need 15 beds for acute admissions and 10 longer stay beds for disturbed and aggressive psychotic patients (Andrews 1991 ).
Patients with schizophrenia will utilize half these beds. Those especially in need of admission would be patients in whom comorbidity from other conditions such as alcoholism, drug abuse, antisocial personality, or mental subnormality made treatment in the community very difficult.
The problems likely to be encountered in developing a comprehensive program of treatment in the community were outlined by Talbott (1979) and little has changed since then. Money has not followed the transfer of patients into the community. Some funds are still bound up in the half empty mental hospitals, but even when the hospitals are closed, very little is spent on the capital works that a community service needs. Psychiatric treatment in the community is a highly skilled and complicated exercise; it is not synonymous with semiskilled welfare-type care. Staff who do work in the community are too often ill-trained and ill-managed. Many who are competent leave. Those who remain are required to work in conditions that are markedly inferior to those that exist in the local district or general hospital. In part this is because no one seems to have developed a strategy whereby power-or at least some of the correlates of power such as money, fame, and happiness-can be transferred from the hospital to the community. The powerful hospital professorial department is still the model that new clinicians seek to emulate. Virtually nowhere in the world is there a community-based department of psychiatry that is paramount in teaching, clinical care, and research, or one that is anywhere as powerful as the entrenched hospital department. Until this change occurs, and until exemplary facilities for teaching and research encourage good students to work and do research in the community, programs of community treatment will be at risk of being seen as second best, despite the economic and patient care advantages that such treatment provides to the wider community.
